Allogene Therapeutics, Inc. (ALLO) Tops Q2 EPS by 4c

Allogene Therapeutics, Inc. (NASDAQ: ALLO) reported Q2 EPS of ($0.23), $0.04 better than the analyst estimate of ($0.27).

For earnings history and earnings-related data on Allogene Therapeutics, Inc. (ALLO) click here.

You May Also Be Interested In

• Walmart (WMT) PT Lowered to $130 at UBS on Investment Narrative's Competing Dynamics
• Can Anthropic actually match or beat SpaceX’s IPO? Numbers say "Yes, but"
• AAON rebrands its enterprise identity as The Aaon Group